Olanzapine for psychosis in patients with Parkinson's disease with and without dementia.
about
The Efficacy and Safety of Antipsychotic Medications in the Treatment of Psychosis in Patients with Parkinson's DiseaseUse of atypical antipsychotics in the elderly: a clinical reviewAntipsychotics for the management of psychosis in Parkinson's disease: systematic review and meta-analysis.Effects of newer antipsychotics on extrapyramidal function.Atypical antipsychotics in Parkinson-sensitive populations.Atypical Antipsychotic Use in the Treatment of Psychosis in Primary CarePsychosis in Parkinson's disease.Cognitive deficits and psychosis in Parkinson's disease: a review of pathophysiology and therapeutic options.Adverse effects of atypical antipsychotics in the elderly: a review.Conventional and atypical antipsychotics in the elderly : a review.A fixed-dose randomized controlled trial of olanzapine for psychosis in Parkinson disease.Phenomenology and management of cognitive and behavioral disorders in Parkinson's disease. Rise and logic of dementia in Parkinson's disease.Olanzapine treatment for dopaminergic-induced hallucinations.Olanzapine as a treatment of neuropsychiatric disorders of Alzheimer's disease and other dementias: a 24-month follow-up of 68 patients.Treatment of dementia with Lewy bodies and Parkinson's disease dementia.Psychiatric complications of drug treatment of Parkinson's disease.Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study.
P2860
Q26738456-2608D925-C63B-4A98-9253-8219E4EC29A4Q26827756-BB10A068-27FC-4954-B953-88E394E79750Q30489967-16080ED6-22AE-480A-96CB-D10146FFD2EDQ34481227-701EA319-E87D-44B9-BCA6-AE051A755BB5Q34851726-0C9069B7-C841-4A43-85DE-00A30D178ECCQ35665593-D68B04A7-6624-48A0-8975-C1FA7EE41370Q35863404-939405FF-A354-4552-A835-294421169B00Q36492310-7377E6BA-CEA7-4A17-A0BD-DC2D9AF58A19Q36677274-65ED7CA0-ECDB-43A2-BB1B-E3FDAE33BE42Q36834289-686B2CFD-4654-484B-B697-26588A5DFFC3Q41812925-A81CB6BC-4F3E-401D-91F3-C3AC22F92CC8Q41838690-31F5CD65-4E62-4605-B404-EC941FDA9658Q44165264-846EAA3D-E9F7-4515-A2DF-CF61F683ED36Q44573608-E99B6963-38E0-4C9B-B6EE-3FC83E02183EQ46643603-0DF04D6B-FF9A-409F-B39F-E1C0CE2A439BQ48701862-46150F5E-327B-41CD-A07A-8AB918B8F450Q51974389-83631666-B0D1-44C1-9767-382DD05210BD
P2860
Olanzapine for psychosis in patients with Parkinson's disease with and without dementia.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh
1999年學術文章
@zh-hant
name
Olanzapine for psychosis in patients with Parkinson's disease with and without dementia.
@en
Olanzapine for psychosis in patients with Parkinson's disease with and without dementia.
@nl
type
label
Olanzapine for psychosis in patients with Parkinson's disease with and without dementia.
@en
Olanzapine for psychosis in patients with Parkinson's disease with and without dementia.
@nl
prefLabel
Olanzapine for psychosis in patients with Parkinson's disease with and without dementia.
@en
Olanzapine for psychosis in patients with Parkinson's disease with and without dementia.
@nl
P2093
P921
P356
P1476
Olanzapine for psychosis in patients with Parkinson's disease with and without dementia.
@en
P2093
P304
P356
10.1176/JNP.11.3.392
P50
P577
1999-01-01T00:00:00Z